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LIST OF ABBREVIATIONS 
ApoE: apolipoprotein E 
TC: total cholesterol 
LDL: low-density lipoprotein 
oxLDL: oxidized LDL 
HDL: high-density lipoprotein 
VLDL: very low-density lipoprotein 
LDLR: LDL receptor 
VLDLR: VLDL receptor 
RA: rheumatoid arthritis 
CIA: collagen type II-induced arthritis 
CVD: cardiovascular disease 
Col II: collagen type II 
CFA: complete Freund’s adjuvant  
TLR: toll-like receptor 
DAMP: endogenous danger-associated molecular pattern 
WT: wild type 
B6: C57BL/6 
NCD: normal chow diet 
HCD: atherogenic hypercholesterolemic diet 
PON-1: paraoxanase 
U/ml: titration units/ml 
RT-qPCR: quantitative real time reverse transcriptase PCR 
IL-1β: interleukin-1β 
TNFα: tumor necrosis factor-α 




Apolipoprotein E (ApoE) deficiency promoted an exacerbation of autoimmune 
arthritis in mice by inducing pro-inflammatory immune responses. In this study we 
analysed the contribution of hypercholesterolemia and/or the absence of ApoE anti-
inflammatory properties, unrelated to its function in the control of cholesterol 
metabolism, towards the acceleration of arthritis in these mutant animals. The induction 
and severity of collagen type II-induced arthritis (CIA) were compared for B10.RIII 







different concentrations of circulating ApoE and cholesterol. A 50-70% reduction in 
serum levels of ApoE was observed in heterozygous B10.RIII.ApoE
+/-
 mice in 
comparison to B10.RIII.WT, although both strains of mice exhibited similar circulating 
lipid profiles. This ApoE reduction was associated with an increased CIA severity that 
remained lower than in homozygous B10.RIII.ApoE
-/-
 mice. An important rise in 
circulating ApoE concentration was observed in hypercholesterolemic B10.RIII.LDLR
-/-
mice fed with a normal chow diet, and both parameters further increased with an 
atherogenic hypercholesterolemic diet. However the severity of CIA in B10.RIII.LDLR
-
/-
mice was similar to that of B10.RIII.WT controls. In conclusion, by comparing the 
evolution of CIA between several strains of mutant mice with different levels of serum 
ApoE and cholesterol, our results demonstrate that both hypercholesterolemia and ApoE 
regulate the intensity of in vivo systemic autoimmune responses. 
  




Rheumatoid arthritis (RA) is a chronic autoimmune disease resulting in joint 
inflammation and destruction. A strong association between RA and an increased risk of 
cardiovascular disease (CVD), due to accelerated atherosclerosis, has been established 
(1, 2). In this regard, different studies show that dyslipidemia is highly prevalent in 
patients with RA and may be present at least 10 years before the onset of the disease (3-
5). However, a relationship between an altered lipid profile in plasma and the 
augmented incidence of CVD in RA patients has not been clearly proven and is still the 
subject of intense debate (6, 7). 
On the other hand, dyslipidemia can trigger or potentiate already existing 
inflammatory responses and thereby enhance the severity of RA. Oxidized low-density 
lipoproteins (oxLDL) that accumulate in the macrophages of the arterial intima during 
hypercholesterolemia are good activators of toll-like receptor 4 (TLR4), acting as 
endogenous danger-associated molecular patterns (DAMP) (8). Also, it has been 
reported that in T cells from systemic lupus erythematosus patients, dyslipidemia may 
potentiate antigen receptor signalling through the increase of glycosphingolipid 
synthesis and their incorporation into membrane lipid rafts (9). Accordingly, a 
relationship between hypercholesterolemia and RA severity has been established (10) 
although it has not been confirmed by others (11). 
Experimental animal models of RA in association with dyslipidemia constitute 
excellent tools to explore some of above mentioned questions. In this regard, we and 
others have recently shown that ApoE (ApoE
-/-
) deficiency exacerbates the development 
of collagen type II (col II)-induced autoimmune arthritis (CIA) in B10.RIII mice in 
association with enhanced Th1 and Th17 inflammatory responses (12) or the semi-
chronic K/BxN serum transfer-induced inflammatory arthritis through the potentiation 
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of innate immune responses (13). Accordingly, these experimental models can be used 
to explore whether the accelerated arthritis observed in ApoE
-/-
 is related to the 
hypercholesterolemia characteristic of these mutant mice and/or to the lack of some of 
the previously identified anti-inflammatory properties of ApoE, that are unrelated to its 
function in the control of cholesterol metabolism (14). In the present study, we have 
explored these questions comparing the severity of CIA between mice expressing 
different amounts of ApoE in the context of either normal or altered circulating 
cholesterol levels.  
 








) and B10.RIII (H-2
r
) mice were purchased 
from Charles River (Barcelona, Spain) and Harlan Iberica (Barcelona, Spain), 
respectively. B6 mice deficient in LDL receptor (B6.LDLR
-/-
) were kindly provided by 
Dr. Jorge Joven, Unitat de Recerca Biomèdica, Hospital Universitari Sant Joan, Institut 
d'Investigació Sanitària Pere Virgili, Universitat Rovira i Virgili, Reus, Spain. 
B10.RIII.ApoE
-/-
 mice were obtained from our animal facilities as described recently 





 and B10.RIII.WT littermates. B10.RIII.LDLR
-/-
mice 
were produced in our animal facilities by backcrossing B6.LDLR
-/-
 mice with B10.RIII 
mice for 7 backcross generations. In the second backcross generation, H-2
r/r
 mice were 





Biosciences, Madrid, Spain). In the last backcross generation, male and female 
heterozygous mice were intercrossed and B10.RIII.LDLR and B10.RIII.WT littermates 
were selected by PCR of genomic DNA extracted from mouse tails. Mice were fed ad 
This article is protected by copyright. All rights reserved.
6 
 
libitum with a normal chow diet (NCD) or an atherogenic hypercholesterolemic diet 
(HCD) (10.8% total fat, 0.75% cholesterol, S4892-E010, Ssniff, Germany) and bled 
from the retro-orbital plexus 4 weeks after immunization. All animal care and 
experimental procedures were carried out according to institutional guidelines and 
approved by the Universidad de Cantabria Institutional Laboratory Animal Care and 
Use Committee (ref 2014/12). 
 
Induction and assessment of arthritis. 
Bovine col II (MD Bioproducts, Zürich, Switzerland), dissolved at a 
concentration of 2 mg/ml in 0.05 M acetic acid, was emulsified with CFA containing 4 
mg/ml of Mycobacterium tuberculosis (MD Bioproducts). For the induction of CIA, 8-
12 week-old male mice were immunized once at the base of the tail with 150 µg of 
antigen in a final volume of 150 µl. A clinical evaluation of arthritis severity was 
performed as described (15). 
Radiological studies were performed using a CCX Rx ray source of 70 Kw with 
an exposition of 90 ms (Trophy Irix X-Ray System; Kodak Spain, Madrid) and Trophy 
RVG Digital Imagining system as previously described (15). Radiological images were 
scale-graded according to the presence of 4 different radiological lesions (1: soft tissue 
swelling, 2: juxta-articular osteopenia due to alterations in bone density, 3: joint space 
narrowing or disappearance, and 4: bone surface irregularities due to marginal erosions 
and/or periosteal new bone formation). The extension of every individual lesion in each 
paw (local: affecting one digit or one joint in the carpus; diffuse: affecting two or more 
digits and/or two or more joints in the carpus) was graded from 0 to 2 as follows: 0: 
absence; 1: local; 2: diffuse.  
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Flow cytometry studies. 





were stimulated in vitro with concanavalin A (Sigma-Aldrich, St Louis, MO) at a 
concentration of 5 µg/ml or with plastic-bound anti-CD3 (1 µg/well) and anti-CD28 
(0.5 µg/well) mAbs (αCD3/αCD28). The induction of the CD69 and CD25 activation 
markers in CD4
+
 cells was analysed after 3 and 12 hrs of stimulation by flow cytometry 
using commercially labeled antibodies (Biolegend, London, United Kingdom).  




 mice were 
injected ip with 10 µg of LPS (Sigma-Aldrich) or with PBS as a control. Peritoneal cells 













) macrophages characterized by flow cytometry. Cells were 




Total cholesterol (TC), high-density lipoprotein-cholesterol (HDL-c), 
LDL/VLDL-c and triglyceride levels in serum samples were determined using an 
autoanalyzer (Biosystems SA, Barcelona, Spain) following manufacturer instructions. 
Serum levels of IgG1 and IgG2a anti-col II antibodies were measured by ELISA as 
described (12). Results were expressed in titration units/ml (U/ml) in reference to a 
standard curve obtained from a serum pool of col II-CFA immunized DBA/1 mice. 
Circulating levels of ApoE were determined by ELISA as described (16). Briefly, 
microtiter plates (Maxisorp Nunc-immuno plates, ThermoFisher Scentific, Waltham, 
MA) were coated with 0.1 µg/ml of WUE-4 (mouse anti-human ApoE mAb, Novus 
Biologicals, Madrid, Spain) and the assay was developed with goat anti-mouse ApoE 
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(Merck Millipore, Madrid, Spain) followed by a biotinylated rabbit anti-goat antibody 
(Vector Laboratories Burlingame, CA) and streptavidin-alkaline phosphatase (BD 
Biosciences). Results were expressed in µg/ml in reference to a standard curve obtained 
with purified mouse ApoE (a kind gift of Dr. Karl Weisgraber, Gladstone Institute of 
Neurological Disease, University of California San Francisco, CA). 
Mouse HDL from each group was isolated by sequential ultracentrifugation at 
100 000 × g for 24 h at a density of 1.063–1.21 g/ml. HDL composition, including total 
and free cholesterol, triglycerides and phospholipids, was determined by commercial 
methods adapted to the Hitachi 917 autoanalyzer (Roche Diagnostics, Rotkreuz, 
Switzerland). HDL protein concentrations were determined by the bicinchoninic acid 
method (Termo Scientific, Rockford, IL). The ability of HDL to protect against LDL 
oxidation was determined on an assay in which human LDL (0.1mM phospholipids) 
was oxidized alone with 2.5 µM CuSO4 or in the presence of equal concentrations of 
HDL phospholipids from each experimental group (0.1mM phospholipids). The 
oxidation kinetics were followed through continuous monitoring of the formation of 
conjugated diene at 37ºC for 4h (17). The kinetics of LDL in the LDL + HDL 
incubations were calculated by subtracting the kinetics of HDL incubated without LDL. 
The lag phases were calculated and the results represented as relative lag phase to the 
LDL kinetics oxidized without HDL. (17). Paraoxonase (PON)-1 was measured using 
phenylacetate as substrate (17). 
 
Cytokine expression. 
The expression of mRNAs encoding for interleukin-1β (IL-1β), tumor necrosis 
factor-α (TNFα), IL-6, transforming growth factor-β (TGFβ) and IL-10 cytokines was 
explored in the paws before col II immunization and 8 weeks after using quantitative 
This article is protected by copyright. All rights reserved.
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real time reverse transcriptase PCR (RT-qPCR). After skin removal, the paws were kept 
frozen at -70 ºC until processing. Total RNA from powdered paws was obtained by 
TRIzol extraction (Invitrogen, ThermoFisher Scentific). One µg of the isolated RNA 
was used for cDNA synthesis with a RT-PCR kit (Bio-Rad Laboratories, Madrid, 
Spain), according to manufacturer instructions. Quantitative real time PCR (RT-qPCR) 
was performed on a StepOne Plus real time PCR instrument (Applied Biosystems, 
ThermoFisher Scentific) using specific TaqMan expression assays and a universal PCR 
Master Mix (Applied Biosystems, ThermoFisher Scentific). Results (in triplicate) were 
normalized to GAPDH
 
expression and measured in parallel for each sample. 
 
Statistical analysis. 
 The differences between the two groups were analyzed by a 2-tailed Student’s t 




The severity of CIA in ApoE mutant mice directly correlates with the levels of 
circulating ApoE. 
We and others have recently reported the development of an exacerbated 
inflammatory arthritis in mice deficient in ApoE (12, 13). To analyze whether the 
enhanced disease in these mutant mice was related to the hypercholesterolemia and/or to 





 mice. Serum ApoE levels and lipid profiles were 
first analyzed in the different experimental groups. The levels of circulating ApoE in 
heterozygous B10.RIII.ApoE
+/-
 mice were approximately one-third/half of those found 
This article is protected by copyright. All rights reserved.
10 
 
in B10.RIII.WT, both before and after col II immunization (Figure 1A). A significant 
reduction in the levels of circulating TC and HDL-c, but not of LDL/VLDL-c and 
triglycerides, was observed in B10.RIII.WT mice in association with the development 
of CIA (Figure 1B; p<0.05 in both cases). Despite the reduced ApoE concentration, the 
levels of circulating TC, HDL-c, LDL/VLDL-c and triglycerides in B10.RIII.ApoE
+/-
 
before immunization were normal and similar to those of non-immunized B10.RIII.WT 
mice (Figure 1B). Again, reduced levels of circulating TC and HDL-c (p<0.05 and 
p<0.01, respectively) were detected in B10.RIII.ApoE
+/-
 after immunization with col II, 
and these levels remained similar to those of immunized B10.RIII.WT controls (Figure 
1B). As expected, ApoE was undetectable in sera from non-immunized and col II-
immunized B10.RIII.ApoE
-/-
 mice, along with the presence of an abnormal lipid profile 
characterized by increased levels of triglycerides, TC and LDL/VLDL-c (p<0.001 in all 
cases) and normal levels of HDL-c (Figure 1A and B), in comparison to both 
B10.RIII.WT and B10.RIII.ApoE
+/-
 mice.  
As previously described (12), the severity of CIA in B10.RIII.ApoE
-/-
 mice was 
higher than in B10.RIII.WT mice (Figure 2). In inverse correlation with serum levels of 
ApoE, the clinical severity of CIA in B10.RIII.ApoE
+/-
 mice was also significantly 
higher than in B10.RIII.WT controls but lower than in B10.RIII.ApoE
-/-
 mice (Figure 
2A). This was confirmed by analyzing different radiological signs associated with bone 
and cartilage damage. The extent of joint narrowing or disappearance of the 
interosseous spaces, reflecting cartilage loss, and of bone irregularities, secondary to 
periosteal new bone formation and/or marginal articular erosions, was higher in 
B10.RIII.ApoE
-/-
 than in B10.RIII.ApoE
+/-
 mice (Figure 2B and C). Although the degree 
of soft tissue swelling and of juxta-articular osteopenia was also slightly larger in 
B10.RIII.ApoE
-/-
 than in B10.RIII.ApoE
+/-
 mice, these increases were not statistically 
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significant. The severity of all radiological signs was significantly lower in 




 mice (Figure 2B 
and C).  
The accelerated disease in B10.RIII.ApoE
-/-
 mice was shown to correlate with 
qualitative changes in anti-col II humoral immune responses and with an enhanced gene 
expression of arthritogenic cytokines in the paws (12). To explore whether similar 
abnormalities also accounted for the aggressive disease progression in heterozygous 
B10.RIII.ApoE
+/-
 mice, circulating levels of IgG1 and IgG2a anti-col II antibodies were 
first compared in the different experimental groups before CIA induction and 4 weeks 
after. As reported (12), the circulating levels of IgG1 anti-col II antibodies were 
significantly reduced in immunized B10.RIII.ApoE
-/-
 mice in comparison to both 
B10.RIII.WT and B10.RIII.ApoE
+/-
 mice (Figure 3A). Although the levels of IgG1 anti-
col II antibodies also tended to decrease in immunized B10.RIII.ApoE
+/-
 in comparison 
to B10.RIII.WT controls, these differences did not reach statistical significance (Figure 
3A; p= 0.07). No changes in the titers of serum IgG2a anti-col II antibodies were 
observed between the different experimental groups (Figure 3A). 
A significant increased expression of arthritogenic IL-1β, TNFα and IL-6 
mRNAs was observed in the paws of B10.RIII.ApoE
-/-
 in comparison to B10.RIII.WT 
mice 8 weeks after immunization with col II-CFA (Figure 3B). In B10.RIII.ApoE
+/-
 
mice, the expression of IL-1β and TNFα, but not IL-6, mRNAs in the paws was also 
augmented during CIA in comparison to B10.RIII.WT mice (Figure 3B). No changes in 
the expression of the anti-inflammatory cytokines TGFβ and IL-10 were observed 
among the different groups of immunized mice (Figure 3B).  
Different studies indicated that ApoE influenced the in vitro activation of T cells 
and the macrophage polarization into pro-inflammatory M1 cells (18, 19). We then 
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mice correlated with an abnormal T-cell activation and/or an enhanced M1 macrophage 
polarization. No differences in the kinetics of CD69 and CD25 induction were observed 
in CD4
+
 cells from the different strains of mice after concanavalin A or αCD3/αCD28 
stimulation (Figure 4A). However, an altered peritoneal macrophage polarization, 
characterized by an increased M1 polarization and a reduced M2 polarization, was 
observed in B10.RIII.ApoE
-/-
 mice 48 hours after ip injection of LPS in comparison to 
B10.RIII.WT controls (Figure 4B). Again, an intermediate phenotype was observed in 
heterozygous B10.RIII.ApoE
+/-
 mice after LPS treatment (Figure 4B).  
 
Functional properties of HDL in ApoE mutant mice. 
 ApoE is a component of HDL particles (20). In addition, chronic inflammation 
has been shown to alter the anti-inflammatory properties of HDLs transforming them 
into pro-inflammatory molecules (20, 21). Therefore, we next explored whether the 





 mice induced functional changes in these lipoproteins. An 
assessment of the lipid and protein composition of HDLs obtained from each mouse 
genotype revealed significant increases in the distribution of free and esterified 
cholesterol as well as an increase in the percentage of proteins and a reduction in PON-1 
activity in B10.RIII.ApoE
-/-
 mice (Table 1). With the exception of a moderate but 
significant increase in the percentage of proteins, the biochemical composition of HDLs 
from B10.RIII.ApoE
-/-
 mice was similar to that of B10.RIII.WT mice (Table 1).  





 mice, to inhibit the oxidation of 
human LDLs in the presence of CuSO4 was then analyzed. Despite the biochemical 
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differences in the composition of HDLs between B10.RIII.ApoE
-/-
 mice and 
B10.RIII.WT and B10.RIII.ApoE
+/-
 mice, these particles showed a similar anti-oxidant 
capacity in all the experimental groups (Table 1).  
 
Lack of exacerbation of CIA in hypercholesterolemic B10.RIII.LDLR
-/-
 mice in 
association with the increase in serum ApoE levels. 
Although our present observations in B10.RIII.ApoE
+/-
 mice are compatible with 
an immunosuppressive activity of ApoE in vivo, independently of its role in cholesterol 
metabolism, these results cannot formally exclude the participation of 
hypercholesterolemia in the aggravation of CIA in B10.RIII.ApoE
-/-
 mice. To further 
explore this issue we used B10.RIII.LDLR
-/-
 mice. As previously reported (22), these 
mice exhibited increased levels of TC and LDL/VLDL-c in sera when fed with a NCD 
and these levels were even higher under a HCD (Figure 5A: p<0.001 in all cases). These 
abnormal circulating lipid profiles of B10.RIII.LDLR
-/-
 mice were similar before and 
after CIA induction (Figure 5A). In association with the presence of 
hypercholesterolemia, very high levels of circulating ApoE were found in 
B10.RIII.LDLR
-/-
 mice fed with NCD and these levels increased with the HCD, both 
before and after CIA induction (Figure 5B). A significant reduction in circulating TC 
and HDL-c, but not LDL/VLDL-c, concentrations was again observed in B10.RIII.WT 
mice fed with a NCD, but not with a HCD, during the development of CIA, (Figure 
5A). In these WT mice, the type of diet had no effect on serum levels of ApoE neither 
before nor after col II immunization (Figure 5B). 
Regardless of the diet received, no significant differences in the severity of 
clinical and radiological signs were observed between B10.RIII.LDLR
-/-
 and 
B10.RIII.WT mice after CIA induction that were lower than in B10.RIII.ApoE
-/-
 mice 
(Figure 6 A-C). Similarly, paw expression of IL-1β, TNFα and IL-6 mRNAs was 
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significantly lower in B10.RIII.LDLR
-/-
 and B10.RIII.WT mice than in B10.RIII.ApoE
-/-
 
mice 8 weeks after col II immunization (Figure 6D). Again, the expression of TGFβ and 
IL-10 was similar in the different groups of mice after CIA induction (data not shown). 
 
DISCUSSION 
The deficiency of ApoE has recently been shown to exacerbate disease severity 
in two experimental models of autoimmune arthritis in mice by inducing inflammatory 
immune responses (12, 13). However, the underlying mechanisms by which an ApoE 
deficiency promotes such immunological abnormalities have not been clarified. Using 
either normocholesterolemic or hypercholesterolemic mice with different concentrations 
of circulating ApoE, we have demonstrated here that both the hypercholesterolemia and 




While an association between RA and increased risk of atherosclerosis and CVD 
has been strongly established (1, 2), there exist controversies regarding the importance 
of dyslipidemia in this association (3-7). Furthermore, some studies indicate that 
abnormal lipid profiles in sera, defined as high levels of TC and triglycerides and lower 
HDL-c levels, were present in more than 50% of patients with RA before or after 
disease diagnosis (3-5). In contrast, studies show that a significant fraction of RA 
patients exhibit decreased levels of TC and LDL-c and normal values of HDL-c, 
reflecting what has been called the lipid paradox in RA (6, 7). Although the reasons for 
these discrepancies have not been exactly determined, they can be related to differences 
in the inflammatory status of the patients and/or in their dietary habits among the 
different studies. In this regard, we show here that the development of CIA in both 
B10.RIII.WT and B10.RIII.ApoE
+/-
 mice is associated with a reduction in serum levels 
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of TC and HDL-c, but not of LDL/VLDL-c and triglycerides, when fed using NCD, but 
not HCD. Furthermore, inflammation or infection has been reported to alter lipid 
profiles in sera, as observed in mice with sepsis (23). 
Previous observations demonstrate that small amounts of ApoE are sufficient to 
normalize plasma cholesterol levels and to inhibit atherosclerosis in mice (24, 25). In 
our present study, we show an aggravation of CIA in B10.RIII.ApoE
+/-
 mice having 30-
50% of the circulating ApoE observed in WT mice but normal cholesterol profiles. 
Independently of these dose-dependent differences, that may be related to the degree of 
systemic inflammation in each experimental model, both studies highlight the anti-
inflammatory role of ApoE in vivo that is unrelated of its activity in the control of 
cholesterol metabolism. The anti-inflammatory activity of ApoE has been demonstrated 
in several studies. ApoE-containing lipoproteins are very efficient suppressing mitogen-
induced proliferative responses of T lymphocytes by reducing the production of IL-2 
(18). ApoE also regulates the TLR4- and TLR3-mediated production of IL-12 (26) and 
prevents the LPS-induced production of cytokines and subsequent death in rodents (27). 
Furthermore, an ectopic ApoE expression in macrophages and monocytes from ApoE
-/-
 
mice suppresses nuclear factor-κB-mediated inflammation by enhancing miR-146a 
levels (28). In this regard, our results indicate that the partial or total ApoE deficiency 
modifies the polarization of macrophages after a potent inflammatory insult in vivo but 
has no effect on the in vitro activation of CD4
+
 cells. The anti-inflammatory capacity of 
ApoE appears to be isoform-dependent, and animals expressing the E4 allele have 
greater inflammatory responses (29). Interestingly, there is one study that shows an 
association between the ApoE4 genotype and bone loss in human RA (30), although it 
has not been confirmed by other authors (31). The similarities observed in the anti-col II 
antibody responses and in the pattern of cytokine expression in the paws during CIA 







 mice suggest that common 
mechanisms are responsible for the accelerated diseases in both strains of mice.  
We show here that the biochemical composition of HDL particles differs 
between B10.RIII.ApoE
-/-
 and WT controls, with an increase and reduction in the 
amount of free and esterified cholesterol in HDLs from mutant mice, respectively. 
Although the molecular basis of this alteration is unknown, it can be related to changes 
in the expression and/or function of the lecithin:cholesterol acyltransferase, an enzyme 
involved in the conversion of phosphatidylcholine and cholesterol into cholesteryl ester 
and lysophosphatidylcholine in plasma and other biological fluids (32). However, these 
differences do not modify their ability to protect against LDL oxidation. This, together 
with the fact that the biochemical composition of HDLs and their in vitro anti-oxidant 
activity are similar in B10.RIII.ApoE
+/-
 and B10.RIII.WT mice, strongly suggests that 
the exacerbation of arthritis observed in ApoE mutant mice is largely independent of 
HDL function. However, since our HDL experiments have been performed in a cell-free 






The link between cholesterol homeostasis and immune system activation has 
been extensively documented in recent years (reviewed in 33). To directly analyze the 
importance of hypercholesterolemia in the control of CIA severity, we have employed 
B10.RIII.LDLR
-/-
 mice. However, the increase in the levels of circulating cholesterol in 
these mice also promotes an important rise in serum ApoE concentration that according 
to previous studies, probably reflects a liver X receptor-dependent adaptive response to 
cholesterol overload (34). In agreement with the observations in B10.RIII.ApoE
+/-
 mice, 
the high levels of ApoE in B10.RIII.LDLR
-/-
 mice could initially anticipate a reduction 
in the severity of CIA in these animals. Nevertheless, the absence of such protection is 
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compatible with a role for hypercholesterolemia as an additional worsening factor for 
CIA severity in B10.RIII.ApoE
-/-
 mice. In this regard, oxLDL and cholesterol crystals 
can act as DAMPs in the macrophages that infiltrate the arterial intima during 
hypercholesterolemia, activating TLR4 and NLRP3 inflammasome signalling pathways, 
respectively (8, 35). Also, hypercholesterolemia can increase the content of lipid rafts in 
the plasma membrane, potentiating antigen receptor signalling in T cells (9). 
ApoE binds to members of the LDLR family, including the LDLR, LDLR-
related protein 1, VLDL receptor (VLDLR) and APOE receptor 2 (36) and several of 
these receptors have been involved in the anti-inflammatory effect of ApoE (19, 37). 
The fact that the severity of CIA in B10.RIII.LDLR
-/-
 mice is lower than in 
B10.RIII.ApoE
-/-
 mice indicates that LDLR is not the main receptor by which ApoE 
modulates CIA severity. Additional experiments are required to clarify the receptor/s 
involved in this protective activity of ApoE. In summary, our present results underline 
the important role played by ApoE and cholesterol in the regulation of inflammatory 
responses during the development of inflammatory arthritis and highlight the 
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PON1 activity (µmol/ml.min) 59.3±1.7 58.8±4.5 45.9±4.9*
†
 
LDL oxidation protection (%) 175.2±8.8 185.1±49.3 167.9±12.1 
HDL was isolated from plasma by sequential ultracentrifugation at 100,000 g for 24 h at a 
density of 1.063-1.21 g/ml, and lipids and protein were determined. Values are expressed as 
relative (%) chemical composition and correspond to HDL preparations isolated from four 
pooled samples of 4-6 mice in each group. Serum plasma arylesterase activity was measured 
using phenylacetate as substrate and EDTA-sensitive plasma arylesterase (PON1) activity 
was calculated by subtracting the EDTA-resistant arylesterase (5 animals/group). Human 
LDL was incubated with 2.5 µM CuSO4 in the presence or absence of purified HDLs 
(0.1mM phospholipids) from each mouse strain (3 purified pools of HDL/group). The 
percentage of protection of LDL oxidation is expressed as the mean ± SD. Values are mean 
± SD. * P<0.05 versus B10.RIII.WT mice. 
†








Figure 1: Serum lipid profiles and ApoE levels in ApoE mutant mice during CIA 





 mice before (NI) and 8 weeks after (Imm) induction of CIA 
determined by ELISA. (B) Serum levels of total cholesterol, HDLc, VLDL/LDLc and 




 mice before (NI) 
and 8 weeks after (Imm) induction of CIA. Representative results of 3 independent 
experiments are expressed as the mean ± SD (8-10 animals/group).Statistic differences 
are indicated as follow: ***p<0.005. 
 





 mice were immunized with col II-CFA. (A) 
Clinical severity of CIA in individual mice 8 weeks after immunization with col II. Bars 





 mice before and 8 weeks 
after immunization with col II. (C) Severity score of individual radiological signs, 
expressed as the mean ± SD (n= 7-10 mice/group), 8 weeks after immunization. Bars 
represent the mean values. Results from A to C are representative of 4 independent 
experiments. Statistical differences are indicated as follows: ns: non-significant, 
*p<0.05, **p<0.01, ***p<0.005. 
 
Figure 3: Anti-col II humoral responses and cytokine gene expression in ApoE 
mutant mice. (A) Serum levels of IgG1 and IgG2a anti-col II antibodies in individual 
mice before (NI) and 4 weeks after (Imm) immunization with col II. Bars represent the 
mean values. Results are representative of 2 independent experiments. (B) Analysis by 
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 mice before (NI; closed bars) and 8 weeks after 
(Imm; open bars) immunization with col II. Representative results from one out three 
independent experiments (6-8 animals/group) are expressed as the mean ± SD fold 
change of each cytokine relative to GAPDH expression measured in parallel in each 
sample. Statistical differences are indicated as follows: ns: non-significant, *p<0.05, 
**p<0.01. 
 
Figure 4: Effects of ApoE deficiency on the activation of CD4
+
 cells and in M1/M2 





 mice were stimulated in vitro with concanavalin A or with 
αCD3/αCD28, and the kinetics of CD69 and CD25 induction was analyzed by flow 
cytometry 3 and 12 hrs after. Results are expressed as overlapping representative 
histograms of B10.RIII.WT (thin line), B10.RIII.ApoE
+/-
 (dotted line) and 
B10.RIII.ApoE
-/-





 mice were injected with PBS or 
LPS and the percentages of M1 and M2 macrophages in the peritoneal cavity analyzed 
by flow cytometry 48 hrs later. Representative results of 2 independent experiments are 
expressed as the mean ± SD (3-4 animals/group). Statistical differences are indicated as 
follows: ns: non-significant, *p<0.05. 
 
Figure 5: Serum lipid profiles and ApoE levels in B10.RIII.LDLR
-/-
 mice during 





 mice fed with a NCD or a HCD 
before and 8 weeks after induction of CIA. Representative results of 2 independent 
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experiments are expressed as the mean ± SD (8-10 animals/group). (B) Serum levels of 




 mice fed with a NCD or 
a HCD before and 8 weeks after induction of CIA determined by ELISA. Statistical 
differences are indicated as follows: ns: non-significant, *p<0.05, **p<0.01. 
 
Figure 6: Lack of exacerbation of CIA in B10.RIII.LDLR
-/-





 mice fed with a NCD or a HCD 
were immunized with col II-CFA. (A) Clinical severity of CIA in individual mice 8 
weeks after immunization with col II. Bars represent the mean values. (B) 
Representative radiological images of the front paws from mice before immunization 
with col II and 8 weeks after. (C) Severity score of individual radiological signs, 
expressed as the mean ± SD (n= 6-8 mice/group), 8 weeks after immunization. Bars 
represent the mean values. Results from A to C are representative of 3 independent 
experiments. (D) Expression of IL-1β, TNFα and IL-6 mRNAs by RT-qPCR in the 
paws of the mice fed with NCD (open bars) or HCD (closed bars) 8 weeks after (Imm) 
immunization with col II. For each cytokine analysis, a mixed group of non-immunized 
(NI) mice is included for comparison. Representative results from one out three 
independent experiments (5-9 animals/group) are expressed as mean ± SD fold change 
of each cytokine relative to GAPDH expression measured in parallel in each sample. 
Statistical differences are indicated as follows: ns: non-significant, *p<0.05, **p<0.01, 
*** p<0.005. 
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